CN107373487A - 一种甘氨酸亚铁冲剂 - Google Patents
一种甘氨酸亚铁冲剂 Download PDFInfo
- Publication number
- CN107373487A CN107373487A CN201710593559.3A CN201710593559A CN107373487A CN 107373487 A CN107373487 A CN 107373487A CN 201710593559 A CN201710593559 A CN 201710593559A CN 107373487 A CN107373487 A CN 107373487A
- Authority
- CN
- China
- Prior art keywords
- ferrous bisglycinate
- bisglycinate chelate
- electuary
- ferrous
- chelate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013522 chelant Substances 0.000 title claims abstract description 55
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 title claims abstract description 53
- 229940086413 ferrous bisglycinate Drugs 0.000 title claims abstract description 53
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 42
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 229910052742 iron Inorganic materials 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 19
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 239000001259 polydextrose Substances 0.000 claims abstract description 19
- 229940035035 polydextrose Drugs 0.000 claims abstract description 19
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 14
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 14
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000010521 absorption reaction Methods 0.000 abstract description 13
- 210000003754 fetus Anatomy 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 210000002826 placenta Anatomy 0.000 abstract description 3
- 210000000813 small intestine Anatomy 0.000 abstract description 3
- 210000004051 gastric juice Anatomy 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000003743 erythrocyte Anatomy 0.000 description 40
- 102000001554 Hemoglobins Human genes 0.000 description 21
- 108010054147 Hemoglobins Proteins 0.000 description 21
- 208000007502 anemia Diseases 0.000 description 14
- 239000000306 component Substances 0.000 description 13
- 238000007689 inspection Methods 0.000 description 10
- 241001247821 Ziziphus Species 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical class [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- -1 supply energy Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁0.05‑5%,维生素C 0.1‑5%,红枣粉10‑30%,葡萄糖5‑15%,聚葡萄糖5‑15%,麦芽糊精50‑80%;上述成分的百分比之和为100%。本发明的有益效果是:枣粉中含有的活性成分以及维生素C能和甘氨酸亚铁在动物胃肠道进行包合,协助甘氨酸亚铁对抗胃酸等复杂环境变化,在到达动物主要消化器官小肠后促进甘氨酸亚铁的溶解和吸收,起到协同增效作用,可极大提高甘氨酸亚铁的吸收利用率,同时枣粉本身也含有铁,补气血的同时滋养脾胃,达到标本兼治的功效。能够有效改善孕产妇、儿童或成人的铁缺乏症状,可直接通过胎盘,使胎儿及时得到铁的补充,口感舒适,孕妇、儿童可以接受。
Description
技术领域
本发明属于甘氨酸亚铁营养组合物技术领域,具体的说涉及一种甘氨酸亚铁冲剂。
背景技术
铁是人体需要量最大,又最易缺乏的一种微量元素,是构成血液不可缺少的重要成分,许多生命活动都需要铁参加。缺铁性贫血(IDA)是当今世界上普遍存在、需要大力防治的一种常见营养缺乏病。缺铁性贫血对人体的健康具有十分严重的危害,易致各类人群免疫力下降。
孕产妇对铁的需求:妇女在怀孕期间比其他人群更可能出现缺铁性贫血,其原因在于,怀孕时母体内血容量扩张,胎儿和胎盘快速增长,因而使铁需要量猛然增加,此时的孕妇不但每天要供给自身需要的铁营养,而且还要为胎儿的生长发育提供足够的铁营养,因此孕妇都在自己一个人努力摄入铁来供给母婴两个人使用,这样就必然带来铁的需求量过大而供给量不足的问题,尤其需要注意的是,妊娠后半期所需要的铁的数量非常不容易由日常膳食来满足,因此孕妇缺铁的危险性非常高。
孕产妇缺铁(血)的危害:缺铁性贫血对孕妇及胎儿均有一定的危害性。孕妇贫血可诱发妊娠高血压综合征,而且子痫的发生率也会增高;贫血可使孕妇抗病能力降低而发生感染,严重贫血可因心肌供氧不足而导致心力衰竭,甚至危及生命。对胎儿来说,妊娠贫血更有很多不利影响,因贫血使子宫缺血缺氧,胎盘灌注不足,氧的供应不够而导致胎儿在宫内生长发育迟缓或早产,甚至可引起宫内死亡或死产、新生儿缺氧缺血性脑病等。
同时缺铁性贫血使儿童和青少年智力发育及学习能力降低,IQ积分低,成绩下降等;成年人工作效率低,易疲劳;孕产妇健康水平低下,同时可引起胎儿及乳儿贫血。据最新统计结果表明,全世界约有11.2亿人患病,21.5亿患有不同程度的铁缺乏,且尤以发展中国家多见。我国营养调查结果显示,18~60岁人群中,贫血患者约为25%,学龄前儿童约23.35%。
目前补铁(血)的产品:中药类:阿胶类口服液,此类成分有活血的作用,使用不当容易出现流产。硫酸亚铁 、碳酸亚铁 :此类产品化学性质很活泼,易与硫化物、多酚等结合引起食品变色、变质,并且存在严重的肠胃刺激等缺点,分子团有较大,不利于人体吸收。中药类补血产品:一般人群对中药可以适应,但是孕妇属于特殊人群,某些中药成分对胎儿会产生后天的影响,所以一般也建议孕妇慎用中药类补血产品。乳酸亚铁类:市面上很多此类成分的产品,但是通常产品质量大多很不稳定,颜色和腥味都较重,钙盐和硫酸盐的残留多。
甘氨酸亚铁是一种氨基酸螯合物,它独有的小分子团能完整的通过消化道黏膜,与其它补铁强化剂相比较具有适口性好、副作用小、吸收率高的特点,容易被人体吸收,是一种较理想的铁营养强化剂, 对防止铁营养缺乏,增进健康具有重要意义。但由于人体肠胃环境非常复杂,甘氨酸亚铁往往在到达主要吸收器官小肠前就已经遭到破坏,因此防止亚铁氧化,提高铁的吸收率成为目前行业的难题。
发明内容
本发明的目的是为克服甘氨酸亚铁稳定性差、生物利用率低的缺陷,提供了一种甘氨酸亚铁冲剂。
为实现上述目的,本发明采用下述技术方案:
一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁0.05-5%,维生素C0.1-5%, 红枣粉10-30%,葡萄糖5-15%,聚葡萄糖5-15%,麦芽糊精50-80%;上述成分的百分比之和为100%。
优选的,包括如下质量百分比的活性成分:甘氨酸亚铁0.1-1%,维生素C 0.2-2%,红枣粉15-25%,葡萄糖8-12%,聚葡萄糖8-12%,麦芽糊精55-65%;上述成分的百分比之和为100%。
优选的,包括如下质量百分比的活性成分:甘氨酸亚铁0.1%,维生素C 0.2%, 红枣粉20%,葡萄糖10%,聚葡萄糖10%,麦芽糊精59.7%;上述成分的百分比之和为100%。
优选的,所述葡萄糖:聚葡萄糖质量比为1:1。
一种甘氨酸亚铁冲剂的制备方法,将上述原料真空干燥、粉碎、混合均匀即得。
一种甘氨酸亚铁冲剂的作用为预防和改善缺铁性贫血、促进生长发育。
其中:
甘氨酸亚铁具有肠道吸收的最佳稳定化学分子结构,同时提供了补铁所必须的甘氨酸,使得吸收效果是普通产品的4-10倍。具有生物效价高、无毒副作用、无刺激性、适口性好、增强人体免疫功能、无与其他微量元素的拮抗等特点。
枣粉中含有多种生物活性物质,如大枣多糖、黄酮类、皂苷类、三萜类、生物碱类、环磷酸腺苷(cAMP)、环磷酸乌苷(cGMP)等,对人体有多种保健治病功效。主要用于中气不足、脾胃虚弱、体倦乏力、食少便溏、血虚萎黄、妇女脏躁等证的治疗,其主要功效如下:
1.抗氧化:枣粉中丰富的维生素C有很强的抗氧化活性及促进胶原蛋白合成的作用,可参与组织细胞的氧化还原反应,与体内多种物质的代谢有关,充足的维生素C能够促进生长发育、增强体力、减轻疲劳。
2.降血压、降胆固醇:枣粉中的维生素P含量为所有果蔬之冠,其具有维持毛细血管通透性,改善微循环从而预防动脉硬化的作用,还可促进维生素C在人体内积蓄。另外,枣中所含的皂类物质,具有调节人体代谢、增强免疫力、抗炎、抗变态反应、降低血糖和胆固醇含量等作用; 含芦丁有保护毛细血管通畅、防止血管壁脆性增加的功能,对高血压、动脉粥样硬化等病有疗效;所含的黄酮类物质可用于高血压和动脉硬化的治疗和预防。
3.保肝护肝:枣粉中的果糖、葡萄糖、低聚糖、酸性多糖参与保肝护肝。枣可使四氯化碳性肝损伤的家兔血清总蛋白与白蛋白明显增加。同时大枣能提高体内单核细胞的吞噬功能,有保护肝脏、增强体力的作用;枣中的维生素C及cAMP等,能减轻化学药物对肝脏的损害,并有促进蛋白质合成,增加血清总蛋白含量的作用。
4.提高免疫力:红枣多糖是大枣粉中重要的活性物质,其有明显的补体活性和促进淋巴细胞增殖作用,可提高机体免疫力。
聚葡萄糖是一种具有保健功能性的食品组分,可以补充人体所需的水溶性膳食纤维。进入人体消化系统后,产生特殊的生理代谢功能,从而防治便秘,脂肪沉积。其主要作用如下:
1.调节脂类代谢:聚葡萄糖可在小肠内造成一层膜,并缠裹部分食物脂肪,能有效限制消化道内脂肪的吸收,促进类脂化合物的排泄,增加饱腹感,减少进食量,从而达到调节血脂,减少脂肪堆积,预防肥胖等功效。
2.降低胆固醇:聚葡萄糖能吸附胆汁酸、胆固醇变异原等有机分子,抑制总胆固醇(TC)浓度升高,降低胆酸及盐类的合成与吸收,降低人体血浆和肝脏胆固醇水平,防治冠状动脉硬化,胆石症和预防心脑血管疾病等。
3.减少糖量吸收:聚葡萄糖可阻碍事物与消化液充分接触,抑制增血糖素分泌,促使葡萄糖吸收减慢,从而降低餐后血糖水平,充分发挥胰岛素的作用,防止糖尿病。
4.预防治便秘:聚葡萄糖能在人体肠道中吸水膨胀并保持水分,增加粪便体积,刺激肠道蠕动,加速排便频率,起到润肠通便和预防便秘的作用。
5.能够排毒养颜:聚葡萄糖能有效调节肠道pH值,改善有益细菌的繁殖环境,使双歧杆菌等有益菌群迅速扩大,从而抑制腐生菌生长,防止肠道黏膜萎缩,并及时将体内毒素和代谢废物排泄,避免毒素从皮肤排出,达到美肤养颜的效果和预防痔疮、胃肠炎、结肠癌等疾病的发生。
葡萄糖是生命活动中不可缺少的物质,它在人体内能直接参与新陈代谢过程。能补充体内水分和糖分,具有补充体液、供给能量、补充血糖、强心利尿、解毒等作用。葡萄糖为机体所需能量的主要来源,在体内被氧化成二氧化碳和水并同时供给热量,或以糖原形式贮存,能促进肝脏的解毒功能,对肝脏有保护作用。
麦芽糊精易被人体吸收,具有甜度低,无异味,易消化,低热,溶解性好,发酵性小,填充效果好,不易吸潮,增稠性强,载体性好,稳定性好,难以变质的特性。麦芽糊精含有大量的多糖类,另外还含有钙、铁等对人体有益的微量元素及矿物质,并能促进人体正常的物质代谢。
本发明的有益效果是:1、甘氨酸亚铁是一种螯合物,与其它补铁强化剂相比较具有适口性好、副作用小、吸收率高的特点,吸收利用度和功效是常规铁剂的4-10倍,容易被人体吸收,是一种较理想的铁营养强化剂,对防止铁营养缺乏,增进健康具有重要意义;同时它以螯合铁的形式存在,在生物体内被自主吸收,不与其他食物产生交互作用,安全稳定有效。
2、VC是人体必须的营养素,可以促进肠道对铁的吸收,提高肝脏对铁的利用率有助于治疗缺铁性贫血。
3、红枣为补养佳品, 素有天然维生素丸的美誉,食疗药膳中常加入红枣补养身体,滋润气血,能提升身体的元气,增强免疫力,补气血的同时滋养脾胃,达到标本兼治的功效。
4、有效改善孕产妇、儿童或成人的铁缺乏症状,可直接通过胎盘,使胎儿及时得到铁的补充,口感舒适,孕妇、儿童可以接受。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然, 所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。 基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动 前提下所获得的所有其他实施例,都属于本发明保护的范围。下列实 施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造 厂商所建议的条件,除非特别说明,比例和百分比基于重量。
本发明实施例所用原料均为市售。
实施例1,一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁0.05%,维生素C 0.1%, 红枣粉10%,葡萄糖5%,聚葡萄糖5%,麦芽糊精补足,将上述原料真空干燥、粉碎、混合均匀,即得。
实施例2,一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁0.1%,维生素C 0.2%, 红枣粉10%,葡萄糖5%,聚葡萄糖5%,麦芽糊精补足,将上述原料真空干燥、粉碎、混合均匀,即得。
实施例3,一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁0.5%,维生素C 1%, 红枣粉20%,葡萄糖10%,聚葡萄糖10%,麦芽糊精补足,将上述原料真空干燥、粉碎、混合均匀,即得。
实施例4,一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁1%,维生素C 2%, 红枣粉30%,葡萄糖15%,聚葡萄糖15%,麦芽糊精补足,将上述原料真空干燥、粉碎、混合均匀,即得。
实施例5,一种甘氨酸亚铁冲剂,包括如下质量百分比的活性成分:甘氨酸亚铁5%,维生素C 5%, 红枣粉30%,葡萄糖10%,聚葡萄糖10%,麦芽糊精补足,将上述原料真空干燥、粉碎、混合均匀,即得。
将实施例1-5所得产品依次编号A1-A5,进行相关卫生指标的检测,检测结果如下表1所示,均符合相关指标要求。
表1 A1-A5理化指标和卫生指标检测结果
枣粉中含有的活性成分以及维生素C能和甘氨酸亚铁在动物胃 肠道进行包合,协助甘氨酸亚铁对抗胃酸等复杂环境变化,在到达动 物主要消化器官小肠后促进甘氨酸亚铁的溶解和吸收,起到协同增效 作用,可极大提高甘氨酸亚铁的吸收利用率,同时枣粉本身也含有铁, 补气血的同时滋养脾胃,达到标本兼治的功效。一般临床认为孕妇缺 血的标准:凡血红蛋白<100g/L或红血球<3.00×1012/L,即可诊断 妊娠贫血。
临床资料:
1.刘某,24岁,怀孕25周,经检查血液中血红蛋白(HGB)为87g/L,红血球(RBC)为3.00×1012/L,服用实施例1的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为130g/L,红血球(RBC)为3.90×1012/L,处于正常范围。
2.李某,27岁,怀孕28周,经检查血液中血红蛋白(HGB)为101g/L,红血球(RBC)为3.47×1012/L,服用实施例1的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为128g/L,红血球(RBC)为4.05×1012/L,处于正常范围。
3.张某,28岁,怀孕27周,经检查血液中血红蛋白(HGB)为96g/L,红血球(RBC)为3.23×1012/L,服用实施例2的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为123g/L,红血球(RBC)为4.13×1012/L,处于正常范围。
4.牟某,23岁,怀孕30周,经检查血液中血红蛋白(HGB)为90g/L,红血球(RBC)为3.18×1012/L,服用实施例2的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为115g/L,红血球(RBC)为3.69×1012/L,处于正常范围。
5.陈某,25岁,怀孕33周,经检查血液中血红蛋白(HGB)为100g/L,红血球(RBC)为3.46×1012/L,服用实施例3的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为125g/L,红血球(RBC)为4.00×1012/L,处于正常范围。
6.李某,30岁,怀孕26周,经检查血液中血红蛋白(HGB)为93g/L,红血球(RBC)为3.52×1012/L,服用实施例3的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为128g/L,红血球(RBC)为3.85×1012/L,处于正常范围。
7.高某,29岁,怀孕33周,经检查血液中血红蛋白(HGB)为91g/L,红血球(RBC)为3.18×1012/L,服用实施例4的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为119g/L,红血球(RBC)为3.65×1012/L,处于正常范围。
8.黄某,31岁,怀孕36周,经检查血液中血红蛋白(HGB)为85g/L,红血球(RBC)为2.96×1012/L,服用实施例4的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为120g/L,红血球(RBC)为3.77×1012/L,处于正常范围。
9.欧某,25岁,怀孕26周,经检查血液中血红蛋白(HGB)为92g/L,红血球(RBC)为3.10×1012/L,服用实施例5的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为112g/L,红血球(RBC)为3.59×1012/L,处于正常范围。
10.任某,28岁,怀孕30周,经检查血液中血红蛋白(HGB)为100g/L,红血球(RBC)为3.33×1012/L,服用实施例5的甘氨酸亚铁冲剂,服用30天后,血液中血红蛋白(HGB)为115g/L,红血球(RBC)为3.87×1012/L,处于正常范围。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种甘氨酸亚铁冲剂,其特征在于:包括如下质量百分比的活性成分:甘氨酸亚铁0.05-5%,维生素C 0.1-5%, 红枣粉10-30%,葡萄糖5-15%,聚葡萄糖5-15%,麦芽糊精50-80%;上述成分的百分比之和为100%。
2.根据权利要求1所述的一种甘氨酸亚铁冲剂,其特征在于:包括如下质量百分比的活性成分:甘氨酸亚铁0.1-1%,维生素C 0.2-2%, 红枣粉15-25%,葡萄糖8-12%,聚葡萄糖8-12%,麦芽糊精55-65%;上述成分的百分比之和为100%。
3.根据权利要求1所述的一种甘氨酸亚铁冲剂,其特征在于:包括如下质量百分比的活性成分:甘氨酸亚铁0.1%,维生素C 0.2%, 红枣粉20%,葡萄糖10%,聚葡萄糖10%,麦芽糊精59.7%。
4.权利要求1-3中任一项所述的一种甘氨酸亚铁冲剂的制备方法,其特征在于:将上述原料真空干燥、粉碎、混合均匀即得。
5.权利要求1-3中任一项所述的一种甘氨酸亚铁冲剂的用途为预防和改善缺铁性贫血、促进生长发育。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710593559.3A CN107373487A (zh) | 2017-07-20 | 2017-07-20 | 一种甘氨酸亚铁冲剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710593559.3A CN107373487A (zh) | 2017-07-20 | 2017-07-20 | 一种甘氨酸亚铁冲剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107373487A true CN107373487A (zh) | 2017-11-24 |
Family
ID=60337337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710593559.3A Pending CN107373487A (zh) | 2017-07-20 | 2017-07-20 | 一种甘氨酸亚铁冲剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107373487A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109043547A (zh) * | 2018-07-19 | 2018-12-21 | 汉臣氏(沈阳)儿童制品有限公司 | 一种螯合铁多维营养粉及其制备方法 |
CN110464011A (zh) * | 2018-08-07 | 2019-11-19 | 美安康质量检测技术(上海)有限公司 | 一种补血营养粉及其制备方法 |
CN112690437A (zh) * | 2020-12-28 | 2021-04-23 | 湖北省益欣盐产业技术研究院有限公司 | 一种防结块枣盐及其制备方法 |
CN114272337A (zh) * | 2022-01-13 | 2022-04-05 | 开封嘉骏生物科技有限公司 | 一种改善动物贫血的中药制剂及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904507A (zh) * | 2009-06-04 | 2010-12-08 | 上海久健生物科技发展有限公司 | 甘氨酸亚铁营养组合物及其应用 |
ES2551053B1 (es) * | 2015-07-31 | 2016-09-06 | Fertypharm, S.L. | Complemento alimenticio polivitamínico para mujeres embarazadas |
-
2017
- 2017-07-20 CN CN201710593559.3A patent/CN107373487A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904507A (zh) * | 2009-06-04 | 2010-12-08 | 上海久健生物科技发展有限公司 | 甘氨酸亚铁营养组合物及其应用 |
ES2551053B1 (es) * | 2015-07-31 | 2016-09-06 | Fertypharm, S.L. | Complemento alimenticio polivitamínico para mujeres embarazadas |
Non-Patent Citations (2)
Title |
---|
无: ""倍恩母品牌系列产品介绍"", 《HTTP://NEWS.QICHACHA.COM/POSTNEWS_5BC9ED52DCD299C1BA5302EA715B5EFE.HTML》 * |
赵欣华: ""易生雪甘氨酸亚铁颗粒用于孕产妇缺铁性贫血临床疗效观察"", 《HTTP://WWW.G3MV.COM/YC/2016/614332.HTML》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109043547A (zh) * | 2018-07-19 | 2018-12-21 | 汉臣氏(沈阳)儿童制品有限公司 | 一种螯合铁多维营养粉及其制备方法 |
CN110464011A (zh) * | 2018-08-07 | 2019-11-19 | 美安康质量检测技术(上海)有限公司 | 一种补血营养粉及其制备方法 |
CN112690437A (zh) * | 2020-12-28 | 2021-04-23 | 湖北省益欣盐产业技术研究院有限公司 | 一种防结块枣盐及其制备方法 |
CN112690437B (zh) * | 2020-12-28 | 2022-11-08 | 湖北省益欣盐产业技术研究院有限公司 | 一种防结块枣盐及其制备方法 |
CN114272337A (zh) * | 2022-01-13 | 2022-04-05 | 开封嘉骏生物科技有限公司 | 一种改善动物贫血的中药制剂及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101248900B (zh) | 一种新型固体运动饮料冲剂 | |
CN101049150B (zh) | 有广泛用途的食用营养保健钾盐 | |
CN107373487A (zh) | 一种甘氨酸亚铁冲剂 | |
CN106261763A (zh) | 一种谷物膳食纤维代餐粉及其制备方法 | |
CN103431392B (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
CN107455698A (zh) | 一种用于促进智力发育的海洋多肽特膳食品 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN107581599A (zh) | 一种供产妇自然分娩时食用含短肽的特殊膳食用食品配方 | |
CN102048225B (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
CN104855994A (zh) | 肾病非全营养配方食品 | |
JPS63287462A (ja) | ペプチド栄養剤 | |
KR100874859B1 (ko) | 참외씨를 주원료로 한 건강식품 환의 제조방법 | |
CN109247482A (zh) | 糖尿病患者固体饮料及其制备方法 | |
CN110279048A (zh) | 一种复合果汁功能因子饮料及其制备方法 | |
CN108740620A (zh) | 一种西梅澄清饮料及其制备方法 | |
CN113349377A (zh) | 一种瘦身益生菌软胶囊及其制备方法 | |
WO2022165700A1 (zh) | 一种多肽营养粉及其制备方法 | |
KR20200016608A (ko) | 체중조절용 건강식품 조성물 | |
CN107432478A (zh) | 一种复合亚麻籽油微囊粉及其制备方法 | |
JP2001269135A (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
KR102133015B1 (ko) | 당뇨병 예방용 건강기능식품 조성물 | |
CN102948733B (zh) | 一种特殊食用生命营养液的生产方法和配方 | |
CN105639612A (zh) | 马铃薯粉条的制作方法 | |
CN110959797A (zh) | 一种益生元大豆蛋白肽固体饮料及其制备工艺 | |
CN108464508A (zh) | 一种强化肠道微生态的组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171124 |